Bisphosphonate use and Lung Cancer Incidence and Mortality in Elderly Women
Bisphosphonate use and Lung Cancer Incidence and Mortality in Elderly Women
批准号:
9054813
负责人:
Menghua Tao
金额:
$7.3万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-04-15 至 2018-03-31
关键词:
AddressAdjuvantAreaAspirinBindingBloodBone DiseasesBone ResorptionCalciumCancer EtiologyCancer PatientCancer PrognosisCessation of lifeCohort StudiesColorectal CancerDataDevelopmentDiagnosisDiagnosticDiseaseDrug usageElderly womanEnrollmentEpidemiologic StudiesEtiologyFundingHealthIncidenceIntakeIntervention TrialInvestigationKnowledgeMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMediatingMeta-AnalysisMetastatic Neoplasm to the BoneMetforminMineralsMolecularMultiple MyelomaNon-Small-Cell Lung CarcinomaOlder PopulationOralOsteoclastsOsteoporosisParticipantPatientsPharmaceutical PreparationsPopulationPostmenopausePreventionPrimary PreventionPrognostic FactorPropertyPublic HealthResearchRiskRisk FactorsRoleSmokingStagingStreamSubgroupSurvival RateTestingTobacco smokingUnited States National Institutes of HealthVariantWomanWomen&aposs Healthagedbisphosphonatebonebone losscalcium intakecancer diagnosiscancer riskcancer survivalcancer therapyimprovedinhibitor/antagonistlung cancer preventionlung carcinogenesismalignant breast neoplasmmortalityolder womenprospectiveresearch studytumor progression
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lung cancer has become a problem with major public health significance in women. Although tobacco smoking is the most important risk factor of lung cancer, there is still much of the variation in risk that is not fully explained by smoking. Furthe, although there has been considerable investigation of prognostic factors of lung cancer, our knowledge on factors related to lung cancer survival is still evolving. Osteoporosis is a common disease in aged population with the majority of cases occurring in postmenopausal women. Bisphosphonates, inhibitors of osteoclast-mediated bone resorption, are commonly used in the management of osteoporosis. Experimental studies have shown the anti-cancer properties of bisphosphonates; however, only a few recent epidemiological studies investigated the potential impact of bisphosphonate use on the development and/or progression of cancers, including breast and colorectal cancer. Very limited studies have been conducted to evaluate bisphosphonate use in relation to lung cancer incidence and mortality in older women. Utilizing an existing prospective cohort study of postmenopausal women, the proposed study will investigate relationships between oral bisphosphonate use and lung cancer risk, as well as the association of bisphosphonate use prior to cancer diagnosis with lung cancer survival among postmenopausal women. Results from the proposed study have the potential to provide very important information for understanding how personal use of oral bisphosphonate for another indication might impact on lung cancer development and progression in older women, as well as to improve our understanding about etiology of lung cancer and prognostic factors of lung cancer in women. These understandings would provide first-step data for further intervention trials or investigations of molecular mechanisms of bisphosphonate and lung cancer progression. More importantly, these understandings would have major public health implications for improving lung cancer survival in older women.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1093/annonc/mdy097
发表时间:
2018-06-01
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
作者:
[Tao MH, Chen S, Freudenheim JL, Cauley JA, Johnson KC, Mai X, Sarto GE, Wakelee H, Boffetta P, Wactawski-Wende J]
通讯作者:
Wactawski-Wende J
海外基金